ICS/IUGA 2004 Scientific Podium Poster Session S16 - Clinical Pharmacology and Overactivity - Blue Room:Chaired by Harold Drutz and Alan Wein

Clinical Pharmacology and Overactivity - Blue Room:Chaired by Harold Drutz and Alan Wein

Scientific Podium Poster Session S16

	Friday 27th August 2004
	14:00 - 15:40

Session Schedule

14:00

#139 Does the bladder contractility change with anticholinergic therapy in women with detrusor overactivity?

Hirani K1, Rahmanou P1, Lamba A1, Dostonova A1, Chaliha C1, Khullar V1 1. Department of Urogynaecology, St. Mary's Hospital, Imperial College London

14:07

#140 The Influence of Anticholinergics Used in Incontinence Treatment on Sleep in Healthy Volunteers Aged 50 Years and Older

Diefenbach K1, Arold G1, Wollny A1, Schwantes U2, Haselmann J2, Roots I1 1. Institute of Clinical Pharmacology, Charité - Universitätsmedizin Berlin, 2. Medical Department, Dr. R. Pfleger Chemische Fabrik GmbH

14:15

#141 Solifenacin Statistically Significantly Increased Continence Rates in Subjects With Symptoms of the Overactive Bladder Syndrome

Cardozo L1, Robinson D1, Drogendijk T2, for the Solifenacin Study Group 1 1. King's College Hospital, London, UK, 2. Yamanouchi Europe B.V., Leiderdorp, The Netherlands

14:23

#142 Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study.

Chapple C1 1. Royal Hallamshire Hospital

14:30

#143 Propiverine hydrochloride immediate (IR) and extended release (ER): Comparison of efficacy and tolerability in patients with overactive bladder

Juenemann K1, Hessdoerfer E2, Unamba-Oparah I3, Berse M4, Bruenjes R5, Madersbacher H6, Gramatté T5 1. Dept. Urology, University Hospital Kiel, Germany, 2. Dept. Urology, Berlin, Germany, 3. Dept. Urology, Voerde, Germany, 4. Dept. Urology, Duisburg, Germany, 5. APOGEPHA Dresden, Germany, 6. Neurourology Unit, University Hospital of Innsbruck, Austria

14:38

#144 A Multicenter,Randomized, Placebo-Controlled Trial of Trospium Chloride in Overactive Bladder Patients

Rudy D1, Cline K2, Goldberg K3, Harris R 4 1. North Texas Clinical Research, 2. Regional Urology, LLC, 3. Texas Urology Research, 4. RMD Clinical Research Institute, LLC

14:46

#145 Darifenacin, a muscarinic receptor antagonist with selectivity for M3 receptors, reduces incontinence and nocturia in patients with overactive bladder

Hill S1, Khullar V2 1. Department of Obstetrics and Gynaecology, Queen's Park Hospital, Blackburn, UK, 2. St Mary's NHS Trust (Imperial College, London), London, UK

14:53

#146 Cost-effectiveness of desmopressin tablets (Minirin®) as adjunctive therapy to behavioural changes in the treatment of nocturia in Norway

Mattiasson A 1, Lundegaard Christensen T2, Poulsen P B2, Tangen T3 1. Dept. of Urology, Lund Sweden, 2. MUUSMANN Research & Consulting, Denmark, 3. Serud Medical Research, Norway

15:01

#147 INTRAVESICAL RESINIFERATOXIN FOR THE TREATMENT OF IDIOPATHIC DETRUSOR OVERACTIVITY IN WOMEN: A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED STUDY

Rios L1, Mattos Jr. D 2, Panhoca R 3, Srougi M 4, Bruschini H 4 1. Federal University of São Paulo and Hospital do Servidor Público Estadual de São Paulo, 2. Hospital do Servidor Publico Estadual de São Paulo, 3. Hospital do Servidor Público Estadual de São Paulo, 4. Federal University of São Paulo

15:09

#148 Phase Two Safety and Efficacy Study of Single Dose Intravesical Resiniferatoxin in Patients with Interstitial Cystitis

Payne C1, Mosbaugh P2, Forrest J3, Evans R3, Frumkin L4 1. Stanford University, 2. Indiana University, 3. none, 4. ICOS Corporation

15:17

#149 The Effect of Cannabinoids on Lower Urinary Tract Symptoms in Multiple Sclerosis: a randomised placebo controlled trial (CAMS-LUTS Study)

Freeman R 1, Adekanmi O2, Waterfield M1, Waterfield A1, Bishop R1, Zajicek J3 1. Urogynaecology Unit, Derriford Hospital, Plymouth UK., 2. Urogynaecology Unit, Derriford Hospital, Plymouth UK., 3. Peninsula Medical School, Plymouth UK.

15:24

#150 A possible explanation for the exceptional efficacy of botulinum toxin treatment for detrusor overactivity

Apostolidis A1, Popat R2, Yiangou Y 3, Dasgupta P4, Anand P3, Fowler C J2 1. The National Hospital for Neurology and Neurosurgery,UCLH & The Hammersmith Hospital, Imperial Colle, 2. The National Hospital for Neurology and Neurosurgery,UCLH , 3. The Hammersmith Hospital, Imperial College London, 4. Guys' and St. Thomas' Hospitals

15:32

#151 Botulinum toxin A (BOTOX®) in neurogenic urinary incontinence: Results from a multi-centre randomised, controlled trial

Schurch B1, de Sèze M2, Denys P3, Chartier-Kastler E4, Ismael S5, Haab F6, Everaert K7, Keppenne V8, Plante P9, Perrouin-Verbe B10, Kumar C11, Fraczek S11 1. Univeritatsklinik Balgrist, 2. Hôpital Pellegrin, 3. Hôpital Raymond Poincaré, 4. Group Hospitalier Pitié-Salpétriè, 5. Hôpital de Rothschild, 6. Hôpital Tenon, 7. Ghent University Hospital, 8. CHU Sart Tilman, 9. Hôpital Rangueil, 10. CHU Nantes, 11. Allergan Ltd